Nexalin Technology, INC 8-K filings

Nexalin Technology Inc. reports the resignation of Michael Nketiah, Senior Vice President of Clinical, Quality, & Regulatory Affairs, effective August 16, 2024.

Nexalin Technology believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a recent public offering of 3 million shares.

Nexalin Technology successfully closed a public offering of 3,000,000 shares, raising approximately $5.25 million in gross proceeds.

Nexalin Technology has priced a public offering of 3,000,000 shares of common stock at $1.75 per share, expecting gross proceeds of approximately $5.25 million.

Nexalin Technology has received regulatory approval from the Brazilian Health Regulatory Agency to sell its Gen-2, 15 milliamp neurostimulation device in Brazil.

Nexalin Technology, Inc. received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements and is preparing a plan to regain compliance.

Nexalin Technology, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the exchange.

Nexalin Technology announced positive clinical results for its neurostimulation device and progress on its new Gen-3 HALO Clarity & Virtual Clinic model.

Nexalin Technology stockholders voted to approve a reverse stock split and granted the board authority to determine the split ratio, as well as the ability to adjourn the special meeting if needed to gather more votes.